Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $210.00 at Needham & Company LLC

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target increased by Needham & Company LLC from $205.00 to $210.00 in a research report sent to investors on Wednesday,Benzinga reports. Needham & Company LLC currently has a buy rating on the specialty pharmaceutical company’s stock.

Several other analysts also recently issued reports on JAZZ. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. TD Cowen reduced their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Robert W. Baird lifted their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $182.47.

Jazz Pharmaceuticals Stock Up 3.2 %

Shares of JAZZ opened at $144.17 on Wednesday. The business’s 50 day moving average is $125.42 and its 200 day moving average is $118.44. The company has a market capitalization of $8.72 billion, a PE ratio of 20.31, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals has a 12-month low of $99.06 and a 12-month high of $148.06. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 2,000 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $121.17, for a total transaction of $242,340.00. Following the completion of the transaction, the chief executive officer now owns 427,025 shares in the company, valued at $51,742,619.25. The trade was a 0.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders sold 5,053 shares of company stock worth $617,442. 4.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Large investors have recently bought and sold shares of the business. IFP Advisors Inc purchased a new position in Jazz Pharmaceuticals during the 4th quarter valued at $25,000. Quadrant Capital Group LLC boosted its holdings in Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after acquiring an additional 101 shares during the period. Elequin Capital LP lifted its holdings in shares of Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock worth $26,000 after buying an additional 183 shares during the period. CoreFirst Bank & Trust bought a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth $28,000. Finally, Allianz SE bought a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth $29,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.